Published: 2018-06-22

Comparison of therapeutic effects of monotherapy of chlorpromazine, risperidone and their combination in newly diagnosed schizophrenic patients

Tarun Vijaywargia


Background: This study evaluates and compares how negative and positive symptoms of schizophrenia were influenced with monotherapy with a first-generation anti-psychotic medication (Chlorpromazine) and a second generation anti-psychotic medication (Risperidone) and by their combination, both of which are commonly used in clinical psychiatric practice.

Methods: It was randomized, double-blind, controlled clinical study performed in Indian newly diagnosed schizophrenic patients in the Department of psychiatry from Feb 2003 to March 2004. Patients 18 (eighteen) patients aged 20 to 60 years diagnosed schizophrenics according to ICD-10 Criteria who visited in outpatient department of psychiatry during study period. Three groups of 6 Patient each, group-1 - was treated with oral Chlorpromazine 100 mg 12 hly, group -2 - was treated with oral Risperidone 2mg 12 hly group 3 -was treated with combination of oral Chlorpromazine 100mg 12 hly + oral Risperidone 2 mg 12 hly. How symptomatology in schizophrenic patients affected, is measured by applying various validated psychiatric scales like Brief psychiatric Rating Score (BPRS), Scale for assessment of positive symptom(SAPS), and Scale for Assessment of Negative Symptoms (SANS).

Results: the study showed that the combination therapy of oral Chlorpromazine 100 mg 12 hly + Risperidone 2mg 12 hly had reduced the overall beneficial effects which were achieved with monotherapy of both the drugs.

Conclusions: In this study, the therapeutic effects of combination of oral Chlorpromazine 100 mg 12 hly + Risperidone 2 mg 12 hly found to be reduced on positive symptoms and negative symptoms of schizophrenia, assessed on SAPS and SANS scoring scales when compared with beneficial effects which were achieved with monotherapy of both the drugs.


Chlorpromazine and risperidone, Schizophrenia, Testosterone

Full Text:



American psychiatric association. Diagnostic and statistical manual of mental disorders, 4th edition.’ Text revision. Washington, DC, American psychiatric association; 2000.

Zimmerman M, Mattia JI. Psychiatric diagnosis in clinical practice: Compr Psychiatry. 1999;40:182.

Kahn RS, Devis KL. New developments in dopamine and schizophrenia. In Psychopharmacology: The fourth generation of progress (ed.) F.E. Bloom and DJ Kupter. Raven Press, New York; 1995:1193-1204.

Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin. 2014 Dec 20;41(4):892-9.

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of general psychiatry. 2006 Oct 1;63(10):1079-87.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England J of Medi. 2005 Sep 22;353(12):1209-23.

John MK. Schizophrenia: Pharmacological Treatment: Kaplan and Sadock’s comprehensive textbook of Psychiatry. 10th Edition; 2017;1:1519-1529.

Andreasen NC. The scale for the assessment of Negative symptoms (SANS). Iowa City, IA: University of Iowa; 1983.

Andreasen NC. The scale for the assessment of Positive symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. January 2009;373(9657):31-41.

Biancosino B, Barbui C, Marmai L, Donà S, Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. International Clinical Psychopharmacology. 2005 Nov 1;20(6):305-9.